Filing Analysis
Vivos Inc. filed an amendment to its 8-K to correct typographical errors regarding the appointment of two key executives. The filing confirms the appointments of Brad Allan Weeks as President and David J. Swanberg as Chief Operating Officer, effective September 1, 2025.
🚩 Red Flags
- None identified; this is a corrective amendment for typographical errors.
📋 Key Facts
- Brad Allan Weeks appointed as President; term ends December 31, 2027; annual base salary of $192,000 plus quarterly stock grants of $3,000.
- David J. Swanberg appointed as COO via a consulting agreement; term ends December 31, 2028; monthly fee of $12,000 plus quarterly stock grants of $3,000.
- The filing is an 'Amendment No. 1' to correct typographical errors in the section regarding David J. Swanberg.
- Both executives' roles are effective as of September 1, 2025.
Vivos Inc. announced the appointment of two key executives to its leadership team: Brad Allan Weeks as President and David J. Swanberg as Chief Operating Officer, effective September 1, 2025.
🚩 Red Flags
- The appointment of a COO via a 'Consulting Agreement' rather than a standard employment agreement can sometimes indicate cost-cutting or non-traditional corporate structure, though common in micro-caps.
📋 Key Facts
- Brad Allan Weeks appointed President; term ends Dec 31, 2027; annual base salary of $192,000 plus quarterly stock grants of $3,000.
- David J. Swanberg appointed COO via a consulting agreement; term ends Dec 31, 2028; monthly fee of $12,000 plus quarterly stock grants of $3,000.
- Both appointments are effective retroactively to September 1, 2025.
- Brad Allan Weeks previously served as Business Development Manager for IsoPet® and RadioGel® divisions.
Vivos Inc. announced the formation of Vivos Scientific India LLP, a wholly owned subsidiary in India. The entity is intended to serve as a manufacturing hub and support clinical data generation for FDA processes.
📋 Key Facts
- On September 17, 2025, the Board approved the creation of Vivos Scientific India LLP ('Vivos India').
- Vivos India will be a wholly owned separate legal entity in India.
- The strategic objective is to establish a manufacturing center and expand human therapies.
- The subsidiary aims to generate additional human trial data to support FDA processes.
Vivos Inc. issued a press release announcing encouraging initial results from human clinical trials of its Radiogel™ Precision Radionuclide Therapy. The company is currently assessing data to determine the potential expansion of these human clinical trials.
📋 Key Facts
- Announced initial positive results from human clinical trials for Radiogel™ Precision Radionuclide Therapy on February 4, 2025.
- The company is conducting a detailed assessment of patient data to evaluate expanding the scope of human clinical trials.
- Filed under Item 8.01 (Other Events) regarding clinical trial progress.
Vivos, Inc. completed a Regulation A+ offering of 12.5 million common shares and issued warrants to purchase an additional 6.25 million shares on February 6, 2025. The transaction generated $1.5 million in gross proceeds intended for general working capital.
🚩 Red Flags
- Significant dilution: The issuance of 12.5M shares plus 6.25M potential warrant shares represents a substantial increase in share count.
- Extremely low exercise price ($0.15) for warrants suggests significant downward pressure on stock price upon exercise.
- High share count (453M+) relative to the small amount of capital raised ($1.5M) indicates heavy dilution for minimal liquidity.
📋 Key Facts
- Completed sale of 12,500,000 shares of common stock to an accredited investor via Regulation A+.
- Gross proceeds from the equity sale totaled $1,500,000.
- Issued warrants for 6,250,000 shares at an exercise price of $0.15 per share.
- Warrants expire on June 30, 2028.
- Post-issuance total common stock outstanding is 453,373,806 shares.
Vivos Inc. announced on June 28, 2024, that it has filed an Investigational Device Exemption (IDE) application to initiate human clinical trials for its Radiogel™ Precision Radionuclide Therapy.
📋 Key Facts
- Filed an application for an Investigational Device Exemption (IDE).
- The application is intended to authorize human clinical trials for Radiogel™ Precision Radionuclide Therapy.
- Report date: June 28, 2024; Filing date: July 1, 2024.
Vivos Inc. announced the renewal of an Executive Employment Agreement for CEO Dr. Michael Korenko, effective January 1, 2024.
🚩 Red Flags
- None identified in this specific filing; the renewal suggests management stability rather than departure.
📋 Key Facts
- CEO Dr. Michael Korenko renewed his employment agreement on December 19, 2023.
- The new term is for a period of two years, effective January 1, 2024.
- Base salary is set at $295,500 annually.
- Includes a grant of 20,000 shares of restricted stock vesting over two years in four equal installments.
- Quarterly bonus potential of up to $10,000 per quarter based on Board discretion.